Therefore, cell therapy that uses CRISPR-Cas9 technology to specifically knockout PD-1 in CART-T cells or T cells to improve the anti-tumor activity of effector T cells and overcome drug resistance in advanced metastatic tumors has been clinically proven to be safe and effective. This evidence concerns the gene PDCD1 and neoplasm.